Revelation Biosciences raises $9.6 million through warrant exercise

Revelation Biosciences Inc. (NASDAQ: REVB) announced the exercise of warrants to purchase 4,355,000 shares of common stock at $2.20 per share, generating $9.6 million in gross proceeds.

The clinical-stage life sciences company entered into a definitive agreement for the immediate exercise of warrants originally issued on May 29, 2025. The transaction is expected to close on September 11, 2025, subject to customary closing conditions.

In exchange for exercising the existing warrants, holders will receive new Class I warrants in a private placement. These new warrants can be exercised for up to 13,065,000 shares at $2.20 per share and will have a five-year term beginning after stockholder approval.

The shares underlying the original warrants are registered under an effective Form S-1 registration statement. The company has agreed to file a resale registration statement within 20 days of closing to register the shares underlying the new Class I warrants.

Roth Capital Partners is serving as the company's financial advisor for the transaction. The securities in the private placement have not been registered under the Securities Act of 1933.

Revelation Biosciences focuses on rebalancing inflammation using its proprietary formulation Gemini. The company has ongoing programs evaluating Gemini for post-surgical infection prevention, acute kidney injury prevention, and chronic kidney disease treatment.

You May Also Be Interested In

• Magnolia Said In Lead To Acquire Wildfire For Over $4 Billion - Bloomberg
• Tempest Therapeutics (TPST) files for 2.43M share offering by selling stockholders
• Spyre Therapeutics (SYRE) files mixed shelf